Evidence map›Paper›PMID 26386966›Full record

ArticleCancer immunology, immunotherapy : CII2015

Modification of cytokine-induced killer cells with chimeric antigen receptors (CARs) enhances antitumor immunity to epidermal growth factor receptor (EGFR)-positive malignancies.

Xuequn Ren, Wanli Ma, Hong Lu, Lei Yuan, Lei An, Xicai Wang, Guanchang Cheng, Shuguang Zuo

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer immunology, immunotherapy : CII, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
1.6field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 24 citations in OpenAlex.

  1. Review
  2. Article
  3. Breast cancer immunotherapy: a comprehensive review.Clinical and experimental medicine · 2023
    Review
  4. Review
  5. Review
  6. CSPG4-Specific CAR.CIK Lymphocytes as a Novel Therapy for the Treatment of Multiple Soft-Tissue Sarcoma Histotypes.Clinical cancer research : an official journal of the American Association for Cancer Research · 2020
    Article
  7. Review
  8. Review
  9. Review
  10. Review
  11. Review
  12. Article
  13. Review
  14. Review
  15. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 1 country.

Xuequn RenTranslational Medicine Center, Huaihe Hospital of Henan University, No. 115, Simon Street, Kaifeng, 475001, Henan Province, China.
Wanli MaGeneral Surgery, Huaihe Hospital of Henan University, Kaifeng, 475001, Henan Province, China.
Hong LuDepartment of Oncology, Huaihe Hospital of Henan University, Kaifeng, 475001, Henan Province, China.
Lei YuanExperimental Center of Molecular Medicine, Luohe Medical College, Luohe, 462002, Henan Province, China.
Lei AnTranslational Medicine Center, Huaihe Hospital of Henan University, No. 115, Simon Street, Kaifeng, 475001, Henan Province, China.
Xicai WangTumor Institute of Yunnan Province, The Third Affiliated Hospital of Kunming Medical University (Tumor Hospital of Yunnan Province), Kunming, 650118, Yunnan, China.
Guanchang ChengTranslational Medicine Center, Huaihe Hospital of Henan University, No. 115, Simon Street, Kaifeng, 475001, Henan Province, China. mike0092@126.com.
Shuguang ZuoTranslational Medicine Center, Huaihe Hospital of Henan University, No. 115, Simon Street, Kaifeng, 475001, Henan Province, China. dawning.zuo@gmail.com.
Henan University Huaihe Hospital and Huaihe Clinical Institute · CNKunming Medical University · CNLuohe Medical College · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Epidermal growth factor receptor (EGFR, ErbB1, Her-1) is a cell surface molecule overexpressing in a variety of human malignancies and, thus, is an excellent target for immunotherapy. Immunotherapy targeting EGFR-overexpressing malignancies using genetically modified immune effector cells is a novel and promising approach. In the present study, we have developed an adoptive cellular immunotherapy strategy based on the chimeric antigen receptor (CAR)-modified cytokine-induced killer (CAR-CIK) cells specific for the tumor cells expressing EGFR. To generate CAR-CIK cells, a lentiviral vector coding the EGFR-specific CAR was constructed and transduced into the CIK cells. The CAR-CIK cells showed significantly enhanced cytotoxicity and increased production of cytokines IFN-γ and IL-2 when co-cultured with EGFR-positive cancer cells. In tumor xenografts, adoptive immunotherapy of CAR-CIK cells could inhibit tumor growth and prolong the survival of EGFR-overexpressing human tumor xenografts. Moreover, tumor growth inhibition and prolonged survival in mice with EGFR(+) human cancer were associated with the increased persistence of CAR-CIK cells in vivo. Our study indicates that modification with EGFR-specific CAR strongly enhances the antitumor activity of the CIK cells against EGFR-positive malignancies.

Indexed as

Immunotherapy, AdoptiveAnimalsCell Line, TumorCytokine-Induced Killer CellsErbB ReceptorsHeterograftsHumansInterferon gamma ReceptorInterleukin-2MiceNeoplasmsReceptors, AntigenReceptors, InterferonEGFR protein, humanErbB ReceptorsInterferon gamma ReceptorInterleukin-2Receptors, AntigenReceptors, InterferonAdoptive cellular immunotherapyChimeric antigen receptorCytokine-induced killer cellsEpidermal growth factor receptor

Identifiers

PMID26386966
PMCPMC11029695
OpenAlexW1919224380

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.